BioAge Labs (NASDAQ:BIOA) Rating Increased to Hold at Wall Street Zen

BioAge Labs (NASDAQ:BIOA) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

A number of other brokerages have also recently commented on BIOA. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research note on Thursday, October 30th. Citigroup raised their target price on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $15.00.

BioAge Labs Stock Up 10.6%

BioAge Labs stock opened at $11.61 on Friday. The stock has a fifty day simple moving average of $7.34. BioAge Labs has a 52-week low of $2.88 and a 52-week high of $20.37. The firm has a market capitalization of $416.22 million, a price-to-earnings ratio of -7.64 and a beta of 1.74.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $2.05 million for the quarter.

Insider Buying and Selling

In other BioAge Labs news, insider Paul D. Rubin sold 68,897 shares of the firm’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $10.19, for a total transaction of $702,060.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 20.82% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of BioAge Labs in the 2nd quarter valued at about $27,000. Russell Investments Group Ltd. acquired a new stake in BioAge Labs during the third quarter worth about $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after acquiring an additional 5,976 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in BioAge Labs in the second quarter valued at approximately $57,000. Finally, Intech Investment Management LLC acquired a new position in BioAge Labs in the second quarter valued at approximately $60,000.

About BioAge Labs

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.